Zöllner, Johann Philipp
Conradi, Nadine
Sauter, Matthias
Knuf, Markus
Knake, Susanne
Kurlemann, Gerhard
Mayer, Thomas
Hertzberg, Christoph
Bertsche, Astrid
Immisch, Ilka
Klein, Karl Martin
Marquard, Klaus
Meyer, Sascha
Noda, Anna H.
von Podewils, Felix
Schäfer, Hannah
Thiels, Charlotte
Zukunft, Bianca
Schubert-Bast, Susanne
Grau, Janina
Willems, Laurent M.
Rosenow, Felix
Reese, Jens-Peter
Strzelczyk, Adam https://orcid.org/0000-0001-6288-9915
Article History
Received: 26 March 2021
Accepted: 10 May 2021
First Online: 28 June 2021
Declarations
:
: This study received ethics approval by the Goethe-University Frankfurt (reference 324/18), and all participants provided informed consent.
: Not applicable.
: JPZ reports speakers’ honoraria and travel grants from Eisai and Desitin Arzneimittel.FR reports personal fees from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Medtronic, Sandoz, Shire, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union.MS reports personal fees from Novartis and GW Pharmaceuticals companies.GK reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, UCB, Novartis, Takeda, and Zogenix.TM reports personal fees and grants from Arvelle Therapeutics, Eisai, GW Pharmaceuticals companies, UCB, and Zogenix.CH reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Shire, and Zogenix.AB reports personal fees from Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Shire/Takeda GmbH, UCB Pharma GmbH, and ViroPharma GmbH.KMK reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai, and GW Pharmaceuticals and grants from the federal state Hessen, through the LOEWE program, and from the Canadian Institutes of Health Research.SM reports grants from Novartis, UCB, Shire, Deutsche Forschungsgemeinschaft, and Epilepsiestiftung Dr. Wolf.FvP reports personal fees and grants from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, Arvelle Therapeutics, Zogenix, and UCB Pharma.SS-B reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB, and Zogenix.AS reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, LivaNova, Marinus Pharma, Medtronic, UCB, and Zogenix.None of the other authors reported any related conflicts of interest.